the total amount paid out in critical illness claims was £75.19m, with cancer accounting for 74 per cent of claims from women, mainly breast cancer, alongside 51 per cent from men.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
.
may 16, 2018
.
.